SCHEMBL10049019

SCHEMBL10049019

CC(C)C(=O)C1CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25714927 0.82 CHRM2 (0.31)
SCHEMBL14214213 0.81
SCHEMBL16492821 0.79
SCHEMBL13989001 0.79
SCHEMBL14050512 0.77
SCHEMBL14050511 0.77 CA2 (0.33)
SCHEMBL24221262 0.76 ALOX5 (0.32)
SCHEMBL18681400 0.75 SMN1; SMN2 (0.33)
SCHEMBL888758 0.74 HPGD (0.45)
SCHEMBL888750 0.74 HPGD (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787788-B2 Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof CAPELLA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-11713322-B2 Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer CAPELLA THERAPEUTICS, INC. (US) 2023-08-01 US disclosed
US-20230212164-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-07-06 US disclosed
US-20180134684-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-05-17 US disclosed
US-20180009779-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-01-11 US disclosed
US-20170183330-A1 BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER CAPELLA THERAPEUTICS, INC. (US) 2017-06-29 US disclosed
US-20170174697-A1 BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER CAPELLA THERAPEUTICS, INC. 2017-06-22 US disclosed
US-20170088582-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. (US) 2017-03-30 US disclosed
US-20170037085-A1 PEPTIDOMIMETIC COMPOUNDS NOLIVA THERAPEUTICS LLC (US) 2017-02-09 US disclosed
US-20170037085-A1 PEPTIDOMIMETIC COMPOUNDS NOLIVA THERAPEUTICS LLC (US) 2017-02-09 US disclosed
US-9493510-B2 Peptidomimetic compounds NOLIVA THERAPEUTICS LLC (US) 2016-11-15 US disclosed
US-9493510-B2 Peptidomimetic compounds NOLIVA THERAPEUTICS LLC (US) 2016-11-15 US disclosed
WO-2016050209-A1 HETEROFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE, PREPARATION METHOD, AND BIO-RELATED SUBSTANCE 厦门赛诺邦格生物科技有限公司 2016-04-07 WO disclosed
US-20150353606-A1 PEPTIDOMIMETIC COMPOUNDS NOLIVA THERAPEUTICS LLC (US) 2015-12-10 US disclosed
US-20150353606-A1 PEPTIDOMIMETIC COMPOUNDS NOLIVA THERAPEUTICS LLC (US) 2015-12-10 US disclosed
US-8110211-B2 Medicated coatings for implantable medical devices including polyacrylates ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2012-02-07 US disclosed
US-20100298270-A1 Novel Compounds and Methods of Using Them SYNDAX PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed